Alvine Pharmaceuticals (Asstes) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Alvine Pharmaceuticals (Asstes) General Information

Description

The assets include ALV003, a mixture of two gluten-specific recombinant proteases engineered to digest gluten and to treat patients with celiac disease. Latiglutenase (formerly known as ALV003 and renamed IMGX-003) is an orally administered mixture of two recombinant gluten-specific proteases including glutamine-specific cysteine protease (EP-B2) and a proline-specific prolyl endopeptidase (PEP) to treat celiac disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Acquirer
ImmunogenX
Primary Office
  • Shoreway Road
  • Suite B
  • San Carlos, CA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alvine Pharmaceuticals (Asstes) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alvine Pharmaceuticals (Asstes)‘s full profile, request access.

Request a free trial